Refer to the USPSTF procedure manual for further details.12 Figure 2. Literature Search Flow Diagram: Medication Use for the Risk Reduction of Primary Breast Cancer in Women View LargeDownload KQ indicates key question. aForty-six studies in 82 publications provided data; some addressed more than...
Sumatriptan for migraines; Finasteride for men with enlarged prostate glands; Calcitonin to help bone loss in women with osteoporosis; Patient-controlled analgesia (PCA) for patients suffering from postoperative or cancer pain; ...
In addition, the pathphysiology ofbone loss from aromatase inhibitors in women, gonadotropin-releasing hormone agonists in men, anticonvulsant medications,and proton pump inhibitors is outlined. Finally, this review offers suggestions on evaluation and management of bone healthin individuals treated with ...
Bone-modifying agents (BMAs) are integral to managing patients with advanced cancer. They improve quality of survival by reducing skeletal-related events, treating hypercalcaemia and chemotherapy-induced bone loss (Coleman in Clin Cancer Res 12: 6243s–6
Antiseizure medications (ASMs) impact bone density, metabolism, micro-architecture and strength.There is a need for standardized methodologies in preclinical research on ASMs.ASM-induced bone adversities are not exclusive to enzyme-inducing ASMs.Conflicting data on bone-specific effects of ASMs, emphasiz...
Myfembree contains relugolix, which decreases the amount of estrogen and other hormones that are produced by the ovaries; estradiol, an estrogen) that may lower the risk of bone loss; and norethindrone acetate, a progestin that is necessary when women with a uterus take estrogen....
It has been found to be excreted from rat milk and is not recommended for lactating women. Disable. There may be Wrights syndrome. Prolonged heavy use can affect platelet function, such as neonatal vitamin K deficiency, which can lead to hypoxemia. The blood concentration in the mothers milk ...
This article reviews existing and emerging data pertaining to the issue of Depo- Provera and its potential deleterious effect on bone mineral density (BMD)... G Ba - 《Journal of Family Planning & Reproductive Health Care》 被引量: 19发表: 2002年 The use of bisphosphonates in women: when ...
in the maxillofacial region which has persisted for more than 8 weeks. The patient must have no history of radiation therapy or metastatic disease to the jaws and has had a current or previous treatment regime with antiresorptive therapy or antiangiogenic medications [4]. At present, bone-modify...
Estrogen replacement therapy and fractures in older women. Ann Intern Med. 1995;1229- 16PubMedGoogle ScholarCrossref 53. Ettinger BGenant HKCann CE Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med. 1985;102319- 324PubMedGoogle ScholarCrossref 54. Paganini...